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OBJECTIVE — The aim of this study was to investigate associations of adiponectin, leptin,
C-reactive protein (CRP), interleukin (IL)-6, and serum amyloid A (SAA), individually or in
combinations, with risk of incident type 2 diabetes in a Aboriginal Canadian population.
RESEARCH DESIGN AND METHODS — Of the 606 Sandy Lake Health and Diabetes
Projectcohortsubjectswhowerefreeofdiabetesatbaseline,540(89.1%)participatedin10-year
follow-up assessments. Concentrations of fasting adiponectin, leptin, CRP, IL-6, SAA, and co-
variates were measured at baseline. Fasting glucose and a 75-g oral glucose tolerance test were
obtained at baseline and follow-up to determine incident type 2 diabetes, deﬁned as clinically
diagnosed type 2 diabetes or as fasting plasma glucose 7.0 mmol/l or 2-h postload plasma
glucose 11.1 mmol/l at follow-up.
RESULTS — Low adiponectin, high leptin, and low adiponectin-to-leptin ratio at baseline
were associated with increased risk of incident type 2 diabetes after adjustment for age, sex,
triglycerides, HDL cholesterol, hypertension, and impaired glucose tolerance (odds ratio 0.63
[95% CI 0.48–0.83], 1.50 [1.02–2.21], and 0.54 [0.37–0.77], respectively). When the models
were additionally adjusted for waist circumference or BMI, however, only low adiponectin
remained signiﬁcantly associated with increased incident diabetes (0.68 [0.51–0.90]). Combi-
nationsofleptin,CRP,IL-6,and/orSAAwithadiponectin,assessedusingeithertheratioorjoint
effects, did not improve diabetes prediction.
CONCLUSIONS — Low baseline adiponectin is associated with increased risk of incident
type 2 diabetes independent of leptin, CRP, IL-6, SAA, and metabolic syndrome variables
including obesity.
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O
besity is a major risk factor for in-
sulin resistance and type 2 diabetes
(1).Therecentfocusonadiposetis-
sue as an endocrine organ secreting sig-
naling proteins, collectively termed
adipokines, has prompted current inter-
ests in associations of adipokines with in-
sulin resistance and diabetes (1–2).
Although underlying mechanisms have
not been completely explained, adipo-
kines have been linked with obesity-
induced inﬂammation and signaling
pathways that contribute to type 2 diabe-
tes (1). Prospectively, adiponectin, an an-
ti-inﬂammatory, anti-atherogenic, and
insulin-sensitizing adipokine (2,3), has
been inversely associated with the devel-
opment of type 2 diabetes (4–7). Several
studies associated increased baseline lev-
els of inﬂammatory markers, including
interleukin (IL)-6 (8,9) and C-reactive
protein (CRP) (9), with incident type 2
diabetes, while others reported no associ-
ation of IL-6 (4) and CRP (4,8) with the
development of type 2 diabetes after ad-
justment for adiposity measures. In an-
other prospective study, the association
between leptin and diabetes risk was at-
tenuated after adjustment for intra-
abdominal fat (10).
Recent studies have suggested that
adipokines may interact in regulating
metabolic homeostasis (11–12). In a
cross-sectional study, evidence was pre-
sented for CRP inhibiting the binding of
leptin to its receptors and leptin stimulat-
ing expression of CRP (11). Others iden-
tiﬁedtheadiponectin-to-leptin(A/L)ratio
as a reliable marker of insulin resistance
(12).
Nonetheless, limited population-
based data are available on how adipo-
kines in combinations may contribute to
the etiology of diabetes. In addition, pre-
vious prospective investigations on asso-
ciations of adipokines with diabetes
provide inconsistent ﬁndings (4–10).
Among those, only a few have reported
data from studies of North American Ab-
original people (4,5), while no studies
have been conducted among Aboriginal
Canadians in whom diabetes is increas-
ingly prevalent (13). The objective of this
study was to investigate associations of
baseline adiponectin, leptin, CRP, IL-6,
and serum amyloid A (SAA), individually
and/or in combinations, with the devel-
opment of type 2 diabetes in a Aboriginal
Canadian population undergoing rapid
cultural transition.
RESEARCH DESIGN AND
METHODS— The Sandy Lake Health
and Diabetes Project (SLHDP) is an ongo-
ing population-based cohort study de-
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2diabetesanditsassociatedriskfactorsin
an Aboriginal Canadian population. The
research partnership and methodology of
the SLHDP baseline survey have been de-
scribed in detail in a previous publication
(13). Brieﬂy, baseline data were obtained
from 728 of 1,018 (72%) eligible resi-
dents of Sandy Lake First Nation aged
10–79 years between 1993 and 1995
(13). Signed informed consent was ob-
tainedfromallparticipants,andthestudy
wasapprovedbytheSandyLakeFirstNa-
tion Band Council and University of To-
ronto Ethics Review Committee (13).
Between 2003 and 2005, subjects
who were free of diabetes at baseline (n 
606) were contacted to participate in a
10-year follow-up study, and 540
(89.1%) residents were contacted. Resi-
dents who did not return for follow-up
(n  66), compared with respondents,
were slightly younger but were not differ-
ent regarding sex, BMI, or any nontradi-
tional risk factors at baseline, except for
slightly higher adiponectin. Of 540 re-
sponses, 27 (5.0%) deaths were reported
due to cancer (n  6), pneumonia (n 
5), liver cirrhosis (n  3), cardiovascular
disease (n  2), brain tumor or aneurysm
(n2),suicide(n2),andotherinclud-
ing accidents (n  7). In the present
study, we excluded nine subjects with di-
abetes at baseline deﬁned by the revised
1999 World Health Organization diag-
nostic criteria of fasting plasma glucose
(FPG) 7.0 mmol/l or 2-h postload
plasma glucose 11.1 mmol/l. In addi-
tion, subjects who died during follow-up
(n  27, described above) or who had
missing baseline fasting and 2-h postload
glucose values (n  12) were excluded.
Afterexclusions,492menandwomenre-
mained in the present study.
Baseline data collection and
laboratory procedures
At baseline, blood samples were collected
after an 8- to 12-h overnight fast to deter-
mine glucose, insulin, lipid proﬁle, adi-
ponectin, leptin, CRP, IL-6, and SAA
concentrations. A 75-g oral glucose toler-
ancetest(OGTT)wasadministered,anda
second blood sample for glucose was
drawnafter120min.Individualswereex-
cluded from the OGTT if they had physi-
cian-diagnosed diabetes and were
currently receiving medication for diabe-
tes or if they had an FPG level 11.1
mmol/l.
Detailed baseline biochemical analy-
ses have been described in previous pub-
lications (13–16). Glucose concentration
wasdeterminedusingtheglucoseoxidase
method. Fasting plasma insulin concen-
tration was analyzed by radioimmunoas-
say. Triglycerides and HDL and LDL
cholesterol were determined using stan-
dard methods described in the Lipid Re-
search Clinics manual of operations (17).
Serum leptin (interassay coefﬁcient of
variation[CV]4.7%at10.4g/l)andadi-
ponectin (interassay CV 9.3% at 7.5 g/l)
were measured using radioimmunoassay
(Linco Research, St. Louis, MO). SAA and
IL-6 were determined using the enzyme-
linked immunosorbent assay (interassay
CV 11% at 81 mg/l and 10% at 2 ng/l,
respectively) (BioSource International,
Camarillo, CA). CRP concentration was
assessed using the Behring BN 100 and
the N high-sensitivity CRP reagent (inter-
assay CV 5.0% at 12.8 mg/l) (Dade-
Behring, Mississauga, ON).
Anthropometric data including
height, body weight, waist circumference
at the iliac crest, and percent body fat
were collected as described previously
(13). The percentage of body fat was esti-
mated by bioelectrical impedance analy-
sis using the Tanita TBF-201 Body Fat
Analyzer (Tanita, Tokyo, Japan). Systolic
and diastolic blood pressure was mea-
sured with the subject seated at the ap-
pearance of ﬁrst and ﬁfth Korotkoff
sounds, respectively. Hypertension was
deﬁnedasasystolicbloodpressure130
mmHg, a diastolic blood pressure 85
mmHg, or receiving antihypertensive
medication therapy. Each anthropomet-
ric and blood pressure measurement was
performed twice, and the average was
used in analyses. An interviewer-
administered questionnaire indicating
medical history was collected.
Follow-up data collection and
outcome assessment
Incident type 2 diabetes at follow-up was
deﬁned as the presence of any one of the
following: 1) FPG 7.0 mmol/l or 2-h
postload plasma glucose 11.1 mmol/l,
2) current use of insulin or oral hypogly-
cemic agents, or 3) a positive response to
the question, “Have you ever been diag-
nosed with diabetes by a nurse (practitio-
ner) or a doctor?”
Statistical analyses
Distributions of continuous variables
were assessed for normality, and natural
log transformations of skewed variables
were used in subsequent analyses. De-
scriptive statistics for continuous vari-
ablesweresummarizedasthemeanSD
ormedian(25
th–75thpercentile)forvari-
ables with a skewed distribution. Cate-
gorical variables were summarized using
proportions. Baseline characteristics of
subjects with and without incident type 2
diabetes were compared using Welch’s
modiﬁed t test or 
2 test as appropriate.
To assess baseline cross-sectional associ-
ations between adipokines and potential
covariates, Spearman’s rank correlation
analysis was performed with adjustment
for age and sex.
Multivariate logistic regression analy-
sis was conducted to evaluate indepen-
dent associations of baseline adipokines
with incident type 2 diabetes. Each adi-
pokine was tested separately in three
models: model 1, adjusted for age and
sex; model 2, adjusted for the model 1
variablesinadditiontotriglycerides,HDL
cholesterol, hypertension, and impaired
glucose tolerance (IGT); and model 3,
adjusted for the model 2 variables in
addition to waist circumference or BMI.
The OR per 1-SD increase in the corre-
sponding adipokine and 95% CI were
calculated.
Interactions between adipokines and
independentvariablesincludingsex,fast-
ing insulin, fasting and 2-h postload glu-
cose, IGT, waist circumference, and BMI
were assessed by adding an interaction
term into a model adjusted for age, sex,
triglycerides, HDL cholesterol, hyperten-
sion, and waist circumference in addition
to main effects. The A/L ratio was used to
assess the previously proposed combina-
tion effect of adipokines (12). Adipokine
combinations were added into the full
model(model3)toassessjointeffects.To
compare different logistic models in their
capability to discriminate subjects with
and without incident diabetes, the C sta-
tistic, which is analogous to the area un-
der the receiver operating characteristic
curve, was calculated with the signiﬁ-
cance determined using the DeLong algo-
rithm(18).Dataanalyseswereperformed
with the use of SAS software, version 9.1
(SAS Institute, Cary, NC), and with the
consideration of two-sided P  0.05 as
statistically signiﬁcant for all analyses.
RESULTS— Baselinecharacteristicsof
subjects with and without incident type 2
diabetes at follow-up are presented in Ta-
ble 1. Of 492 subjects, 86 (17.5%) devel-
oped type 2 diabetes by follow-up: 72 of
383 subjects (18.8%) were ascertained
using fasting and/or 2-h postload glucose
at follow-up assessments, and 14 of 109
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(12.8%) were ascertained based on self-
reported clinical diagnosis only. Subjects
without blood samples at follow-up com-
paredwiththosewithbloodsampleswere
younger and had lower CRP and higher
adiponectin (all P  0.02) but were not
different according to sex, BMI, or other
nontraditional risk factors (all P  0.05).
Subjects who developed diabetes were
older (P  0.001) and had higher adipos-
itymeasuresincludingbodyweight,BMI,
percentbodyfat,andwaistcircumference
(all P  0.001); lower HDL cholesterol
(P  0.02); higher LDL cholesterol, tri-
glyceride, fasting and 2-h postload glu-
cose, and fasting insulin (all P  0.001);
higher systolic and diastolic blood pres-
sure (both P  0.001); and were more
likely to have had IGT or impaired fasting
glucose at baseline (both P  0.005).
Higher baseline concentrations of CRP,
IL-6, SAA, and leptin were observed
among subjects with incident type 2 dia-
betes than those without diabetes (all P 
0.03),whileadiponectinandtheA/Lratio
were lower at baseline among those with
incident diabetes (both P  0.001).
Using Spearman correlation, adi-
ponectin was signiﬁcantly inversely cor-
related with leptin, CRP, and IL-6 (r 
0.26, 0.25, and 0.16, respectively;
all P  0.001) but not with SAA (online
appendix Table 1 [available at http://
dx.doi.org/10.2337/dc08-0036]). Adi-
posity measures including BMI, percent
body fat, and waist circumference were
inversely correlated with adiponectin
(r  0.36, 0.37, and 0.32, respec-
tively; all P  0.001) and A/L ratio (r 
0.73, 0.75, and 0.70, respectively;
all P  0.001). Adiposity measurements
were positively correlated with leptin,
CRP, IL-6, and SAA (r  0.18–0.77, all
P  0.001). Correlation coefﬁcients of
metabolic measurements with the A/L ra-
tio were stronger than with individual
adiponectin (online appendix Table 1),
except for HDL cholesterol (both r 
0.39, P  0.001).
Multivariatemodelswereconstructed
todeterminewhetheradipokinevariables
were independently associated with inci-
dent type 2 diabetes (Table 2). In the ﬁrst
model adjusted for age and sex, baseline
adiponectin and the A/L ratio were in-
verselyassociatedwithincidenttype2di-
abetes(OR0.57[95%CI0.44–0.73]and
0.43 [0.31–0.59] per 1-SD increase, re-
spectively; both P  0.001), while high
leptin and CRP at baseline predicted inci-
dentdiabetes(2.05[1.44–2.90]and1.48
[1.13–1.95], respectively; both P 
0.005). When the models were further
adjusted for triglycerides, HDL choles-
terol, hypertension, and IGT (model 2),
the associations of adiponectin, the A/L
ratio, and leptin with diabetes were atten-
uated but remained signiﬁcant (0.63
[0.48–0.83],0.54[0.37–0.77],and1.50
[1.02–2.21], respectively; all P  0.04).
In full models additionally adjusted for
waist circumference (model 3), however,
only low adiponectin remained signiﬁ-
cantly associated with incident diabetes
(0.68 [0.51–0.90], P  0.007). Results
forfullmodelsadjustedforBMIweresim-
ilar to those adjusted for waist circumfer-
enceandarethusnotpresentedhere.IL-6
and SAA were not signiﬁcantly associated
with incident diabetes in any model as-
sessed (Table 2).
There were no statistically signiﬁcant
interactions between sex and adipokines
in predicting diabetes (all interaction P 
0.05) (data not shown). Similarly, there
were no signiﬁcant interactions of fasting
insulin, fasting and 2-h postload glucose,
IGT, or waist circumference with adipo-
kines in predicting diabetes (all interac-
tion P  0.05) (data not shown).
When various combinations of leptin
and inﬂammatory markers were added to
a full model (model 3) in addition to pri-
mary exposure to adiponectin, the signif-
icant association between adiponectin
and incident diabetes remained un-
changed (Table 3). C statistics for models
assessing different combinations of joint
effects ranged from 0.753 to 0.755 (P 
Table 1—Baseline characteristics of the Sandy Lake Health and Diabetes Project participants
according to incident type 2 diabetes at follow-up
No diabetes Incident diabetes P
n (%) 406 (82.5) 86 (17.5)
Age (years)* 25.4  13.0 31.5  12.4 0.001
Sex (male/female)† 173/233 (42.6/57.4) 34/52 (39.5/60.5) 0.60
Anthropometry*
Height (cm) 165.3  10.4 166.8  9.1 0.16
Weight (kg) 69.8  18.1 82.0  15.9 0.001
BMI (kg/m
2) 25.4  5.5 29.4  5.3 0.001
Percent body fat (%) 33.0  13.2 40.1  10.3 0.001
Waist circumference (cm) 94.4  14.1 104.7  12.1 0.001
Blood pressure
Systolic blood pressure (mmHg)‡ 113.0 (103.5–120.0) 118.0 (110.0–130.0) 0.001
Diastolic blood pressure (mmHg)* 64.0  11.5 69.9  12.3 0.001
Hypertension†§ 54 (13.3) 29 (33.7) 0.001
Lipid proﬁle
HDL cholesterol (mmol/l)* 1.26  0.28 1.19  0.25 0.02
LDL cholesterol (mmol/l)* 2.42  0.74 2.74  0.66 0.001
Triglycerides (mmol/l)‡ 1.10 (0.81–1.53) 1.48 (1.16–1.82) 0.001
Glucose homeostasis
Fasting glucose (mmol/l)* 5.3  0.46 5.6  0.58 0.001
2-h glucose (mmol/l)* 5.4  1.62 6.5  2.08 0.001
Fasting insulin (pmol/l)‡ 94 (66–131) 123 (91–187) 0.001
IGT† 36 (8.9) 23 (26.7) 0.001
Impaired fasting glucose†¶ 22 (5.4) 10 (11.6) 0.005
Adipokines‡
CRP (mg/l) 1.45 (0.40–4.28) 2.82 (1.24–7.48) 0.001
IL-6 (ng/l) 0.67 (0.33–1.23) 0.83 (0.52–1.38) 0.01
Serum amyloid A (mg/l) 7.04 (4.43–11.1) 8.61 (5.52–14.5) 0.03
Leptin (ng/ml) 10.6 (5.20–19.4) 15.0 (9.40–25.7) 0.001
Adiponectin (g/ml) 14.5 (11.0–19.6) 11.0 (8.01–15.1) 0.001
Adiponectin-to-leptin ratio 1.36 (0.65–3.25) 0.73 (0.36–1.44) 0.001
Data are n (%), mean  SD, and median (25th–75th percentile). Number of subjects (n) for each charac-
teristic varies slightly due to occasional missing values. *Welch’s t test performed. †
2 test performed.
‡Welch’sttestperformedonlogtransformation.§Hypertensionisdeﬁnedasasystolicbloodpressure130
mmHg or diastolic blood pressure 85 mmHg or receiving antihypertensive medication therapy. IGT is
deﬁned as fasting plasma glucose 7.0 mmol/l and 2-h postload glucose 7.8 and 11.1 mmol/l. ¶Im-
paired fasting glucose is deﬁned as fasting plasma glucose 6.1–6.9 mmol/l and 2-h postload glucose 7.8
mmol/l.
Adipokines and incident type 2 diabetes
1412 DIABETES CARE, VOLUME 31, NUMBER 7, JULY 20080.05 for base vs. any subsequent models
in Table 3), which indicated that there
was no additional capacity of these mod-
els to discriminate subjects who devel-
oped diabetes from those who did not
(Table 3).
CONCLUSIONS — Despite signiﬁ-
cant cross-sectional correlations of adi-
ponectin, leptin, CRP, IL-6, SAA, and the
A/Lratiowithmetabolicmeasurementsat
baseline, only low adiponectin, high lep-
tin, and low A/L ratio were signiﬁcantly
associatedwithincidenttype2diabetesin
our multivariate models adjusted for age,
sex, triglycerides, HDL cholesterol, hy-
pertension, and IGT. With an additional
adjustment for abdominal adiposity, our
results provide evidence only for the as-
sociationoflowbaselineadiponectinwith
incidenttype2diabetesat10-yearfollow-
up. Combinations of leptin, CRP, IL-6,
and/or SAA with adiponectin, assessed
using either the ratio or joint effects, did
not improve diabetes prediction.
Our ﬁndings are consistent with
those from the Pima Indian population,
another North American Aboriginal pop-
ulationwiththehighprevalenceofdiabe-
tes (4,5). Using nested case-control data,
Krakoff et al. (4) reported that adiponec-
tin predicted type 2 diabetes in a multi-
variate model adjusted for covariates
including waist circumference (incident
rate ratio 0.63 [95% CI 0.41–0.98], P 
0.04),whileCRPandIL-6didnotpredict
diabetes (P  0.88 and 0.28, respec-
tively). Several other prospective studies
from non-Aboriginal populations have
also supported the association of low adi-
ponectinatbaselinewithincreaseddiabe-
tes risk (6–7). In the Health, Aging, Body
Composition Study of white and black
adults aged 70–79 years, however, adi-
ponectin was not an independent predic-
tor of incident type 2 diabetes after
controlling for metabolic syndrome vari-
ables(19).Itispossiblethatthisinconsis-
tent ﬁnding may be related to reduced
renal function in these older subjects,
which has been demonstrated to result in
paradoxically elevated adiponectin levels
(20).
Similar to our results, leptin pre-
dicted type 2 diabetes risk among Japa-
nese men in a univariate logistic
regression model (relative risk 1.78 [95%
CI 1.28–2.48]), but the signiﬁcance was
attenuatedwithadditionaladjustmentfor
baseline intra-abdominal fat (P  0.05)
(10). Previous prospective studies evalu-
ating associations of inﬂammatory adipo-
kinemarkerswithdiabetesriskhavebeen
inconsistent. Several studies supported
the association of increased inﬂammatory
marker levels with the development of
type 2 diabetes, including IL-6 (8,9) and
CRP (9), while others reported no associ-
ations of IL-6 (4) and CRP (4,8) with in-
cident type 2 diabetes after adjusting for
adiposity measures. Sex differences in the
prediction of type 2 diabetes by inﬂam-
matory markers have been suggested
(21). However, we did not observe a sig-
niﬁcant interaction between sex and adi-
pokines assessed in the current study
population.
Recently,aninteractionbetweenCRP
and leptin was proposed as a mechanism
contributing to leptin resistance (11). Ev-
idence was presented for human CRP in-
hibiting the binding of leptin to its
receptors in vitro and leptin stimulating
expression of CRP in human primary
Table 2—Multiple logistic regression analyses of the associations of adipokines with incident type 2 diabetes: the Sandy Lake Health and
Diabetes Project
Independent variable SD
Model 1* Model 2† Model 3‡
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Adiponectin 0.49 0.57 (0.44–0.73) 0.001 0.63 (0.48–0.83) 0.001 0.68 (0.51–0.90) 0.007
Leptin 0.92 2.05 (1.44–2.90) 0.001 1.50 (1.02–2.21) 0.04 0.97 (0.58–1.62) 0.89
CRP 1.41 1.48 (1.13–1.95) 0.005 1.29 (0.96–1.73) 0.09 1.05 (0.76–1.46) 0.77
IL-6 1.00 1.23 (0.96–1.57) 0.10 1.11 (0.84–1.45) 0.47 1.03 (0.78–1.36) 0.84
SAA 0.88 1.17 (0.92–1.48) 0.20 1.14 (0.88–1.49) 0.33 1.07 (0.81–1.41) 0.62
A/L 1.11 0.43 (0.31–0.59) 0.001 0.54 (0.37–0.77) 0.001 0.66 (0.42–1.02) 0.06
Data are OR (95% CI) per 1-SD change. n  479 for models including adiponectin and n  490 for models including leptin, CRP, IL-6, or SAA. *Adjusted for age
and sex. †Adjusted for model 1 variables  triglycerides, HDL cholesterol, hypertension, and impaired glucose tolerance. ‡Adjusted for model 2 variables  waist
circumference.
Table 3—Association between adiponectin and incident type 2 diabetes with addition of leptin, CRP, IL-6, and/or SAA: the Sandy Lake Health
and Diabetes Project
Adiponectin Leptin CRP IL-6 SAA C Statistic*
Base model† 0.45 (0.25–0.81) 0.753
 Leptin 0.45 (0.25–0.81) 0.98 (0.55–1.74) 0.753
 CRP 0.45 (0.25–0.81) 0.99 (0.77–1.26) 0.753
 IL-6 0.45 (0.25–0.81) 0.98 (0.74–1.31) 0.753
 SAA 0.46 (0.26–0.81) 1.07 (0.79–1.47) 0.754
 Leptin  CRP 0.45 (0.25–0.81) 1.00 (0.97–1.03) 0.98 (0.77–1.26) 0.753
 Leptin  CRP  IL-6 0.45 (0.25–0.81) 1.00 (0.97–1.03) 0.99 (0.76–1.28) 0.99 (0.72–1.35) 0.753
 Leptin  CRP  IL-6  SAA 0.45 (0.25–0.81) 1.00 (0.97–1.03) 0.95 (0.70–1.27) 0.97 (0.71–1.33) 1.13 (0.77–1.65) 0.755
Data are OR (95% CI) per 1-unit change (n  479). *There were no signiﬁcant differences between the C statistics of the baseline model and subsequent models
adjusted with additional adipokine(s). †Outcome  incident diabetes; 1° exposure  adiponectin, with adjustment for age, sex, triglyceride, HDL cholesterol,
hypertension, impaired glucose tolerance, and waist circumference.
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tested the hypothesis that combinational
effects of CRP and leptin would improve
predictionofdiabetesriskcomparedwith
individual CRP or leptin. However, we
found that the combinational effect of
CRPandleptinwasnotsigniﬁcantlyasso-
ciatedwithincidentdiabetes.Inaddition,
other joint effect combinations assessed
by adding leptin, CRP, IL-6, and/or SAA
into the full model adjusted for metabolic
syndrome variables in addition to pri-
maryexposuretoadiponectindidnotim-
prove diabetes prediction. The A/L ratio
was identiﬁed as a sensitive and reliable
marker of insulin resistance in a cross-
sectional study (12). Although we ob-
servedsimilarcorrelationsinourbaseline
cross-sectional analysis, the A/L ratio was
not signiﬁcantly associated with incident
diabetes in our multivariate model ad-
justed for metabolic syndrome variables
including waist circumference.
The independent role of low adi-
ponectin in predicting diabetes risk is
likely explained by the role of this adipo-
kine in mediating insulin sensitivity and
secretion (2,22). While the molecular
mechanism of adiponectin is not com-
pletely understood, adiponectin has been
linked with multiple signaling pathways
at multiple sites (22–24). Recently, evi-
dence was provided using knockout
mouse models that adiponectin receptor
1 (AdipoR1) mediated 3	 AMP-activated
protein kinase activity, while adiponectin
receptor 2 (AdipoR2) mediated increased
peroxisome proliferator–activated recep-
tor-
ligandactivityinliver(23).Thedis-
ruption of both AdipoR1/R2 abolished
adiponectin binding and action, increas-
ing inﬂammation and oxidative stress,
andthereforeleadingtoinsulinresistance
and marked glucose intolerance (23). In
another mouse model study, decreased
expression of AdipoR1 or AdipoR2 was
associated with reduced insulin-
sensitizing effects of adiponectin in hepa-
tocytes and myocytes (24). In -cells of
insulin-resistant mice, adiponectin mod-
ulated insulin secretion (22). These pro-
posed roles and mechanisms of multiple
adiponectin-mediated pathways offer ex-
planations for the association of low adi-
ponectinwithdiabetesriskandpotentialfor
understanding the etiology of diabetes.
Limitations of our study include stra-
tegic difﬁculties conducting investiga-
tions in a remote Aboriginal community.
We were unable to collect interim data to
analyze the time to onset of diabetes. We
were also unable to obtain follow-up
blood samples from all subjects: diabetes
outcome assessments of 109 (22.2%)
subjects were by self-reported clinical di-
agnosis only. This 22.2% without blood
samples might have caused underreport-
ing of incident diabetes. The ratio of
plasma high–molecular weight adiponec-
tin to total adiponectin has been corre-
lated more tightly with 2-h postload
glucose than total adiponectin (r 
0.58 for the ratio and 0.38 for total
adiponectin; both P  0.001) (25). How-
ever, in this prospective cohort study,
high–molecular weight adiponectin anal-
ysis was not available at the time of base-
line biochemical data analysis, another
limitation of our study. Nonetheless, the
current study was able to retain a high
10-year follow-up rate of 89.1%. In addi-
tion, investigating the association of a
number of adipokines with incident
type 2 diabetes in an Aboriginal Cana-
dian population with a high prevalence
of diabetes offers a unique perspective.
In summary, low adiponectin was in-
dependently associated with increased
type 2 diabetes risk, while leptin, CRP,
IL-6, and SAA were not associated with
incident type 2 diabetes after adjustment
for metabolic syndrome variables includ-
ing abdominal adiposity in this Aborigi-
nal Canadian population. Combinational
effects of leptin, CRP, IL-6, and/or SAA
with adiponectin, assessed using the ratio
andjointeffects,didnotimprovediabetes
prediction. The strong association be-
tweenadiponectinandincidenttype2di-
abetes, independent of obesity, suggests
that adiponectin may be involved in the
etiology of diabetes.
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